WO1995016691A1 - Rapamycin derivatives useful as immunosuppressants - Google Patents
Rapamycin derivatives useful as immunosuppressants Download PDFInfo
- Publication number
- WO1995016691A1 WO1995016691A1 PCT/EP1994/004191 EP9404191W WO9516691A1 WO 1995016691 A1 WO1995016691 A1 WO 1995016691A1 EP 9404191 W EP9404191 W EP 9404191W WO 9516691 A1 WO9516691 A1 WO 9516691A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- formula
- demethoxy
- compound
- iii
- Prior art date
Links
- 0 C[C@](*)[C@](CC([C@](C)C=C)=*)OC([C@](CCCC1)N1C(C([C@]1(O)O[C@](C[C@](C(C)=CC=CC=C[C@@](C)C[C@@](C)C([C@@]([C@@](C(C)=C)O)OC)=*)O*)CC[C@]1C)=O)=O)=O Chemical compound C[C@](*)[C@](CC([C@](C)C=C)=*)OC([C@](CCCC1)N1C(C([C@]1(O)O[C@](C[C@](C(C)=CC=CC=C[C@@](C)C[C@@](C)C([C@@]([C@@](C(C)=C)O)OC)=*)O*)CC[C@]1C)=O)=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Definitions
- This invention comprises novel demethoxy derivatives of rapamycin, such derivatives having pharmaceutical utility, especially as immunosuppressants.
- Rapamycin is a known macrolide antibiotic produced by Streptomvces hvgroscopicus. having the structure depicted in Formula A:
- Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity.
- rapamycin is highly insoluble, making it difficult to formulate stable galenic compositions. Numerous derivatives of rapamycin are known. Certain 16-O-substituted rapamycins are disclosed in WO 94/02136, the contents of which are incorporated herein by reference.
- 40-O- substituted rapamycins are described in, e.g., in US 5 258 389 and PCT/EP 93/02604 (O-aryl and O-alkyl rapamycins); WO 92/05179 (carboxylic acid esters), US 5 1 18 677 (amide esters), US 5 1 18 678 (carbamates), US 5 100 883 (fluorinated esters), US 5 151 413 (acetals), and US 5 120 842 (silyl ethers), all of which are incorporated herein by reference.
- 32-O-dihydro or substituted rapamycin are described, e.g., in US 5 256 790, incorporated herein by reference.
- novel demethoxy derivatives of rapamycin have an improved pharmacological profile over rapamycin, exhibit greater stability and bioavailability, allow for greater ease in producing galenic formulations, and are more potent immunosuppressants.
- the Novel Compounds comprise rapamycins wherein the methoxy group(s) at position 16 and/or position 39 of rapamycin is deleted and replaced with a selected substituent.
- the Novel Compounds particularly include rapamycins (i) wherein the methoxy group at the 16 position is replaced with another substituent, preferably (optionally hydroxy-substituted) alkynyloxy, and or (ii) wherein the methoxy group at the 39 position is deleted together with the 39 carbon so that the cyclohexyl ring of rapamycin becomes a cyclopentyl ring lacking the 39 position methoxy group (i.e., 39-demethoxy-40-desoxy-39-substituted-42-nor-rapamycins, sometimes referred to herein simply as cyclopentyl rapamycins).
- rapamycins i) wherein the methoxy group at the 16 position is replaced with another substituent, preferably (optionally hydroxy-substituted) alkynyloxy, and or (ii) wherein the methoxy group at the 39 position is deleted together with the 39 carbon so that the cyclohexyl ring
- the remainder of the molecule is as for rapamycin or its immunosuppressive derivatives and analogues, e.g., as described above.
- the molecule is further modified, e.g., such that the hydroxy at the 40- position of rapamycin is alkylated, and or the 32-carbonyl is reduced.
- Novel Compounds are those having the structure of Formula I:
- R is selected from alkyl, alkenyl, alkynyl, hydroxyalkenyl, hydroxyalkyl, hydroxyalkynyl, aryl, thioalkyl, arylalkyl, hydroxyarylalkyl, hydroxyaryl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, alkoxyarylalkyl, haloalkyl, haloaryl, haloarylalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylamidoalkyl, acylamidoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and alkylsilyl; preferably an unsaturated substituent; more preferably an aromatic or
- R 2 is selected from formula II or formula III:
- R 3 is selected from H, alkyl, alkenyl, alkynyl, aryl, thioalkyl, arylalkyl, hydroxyarylalkyl, hydroxyaryl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylamidoalkyl, acylamidoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and alkylsilyl; preferably hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, alkoxyalkyl, and aminoalkyl; especially hydroxyethyl, hydroxypropyl, hydroxyethoxy
- R 4 is H, methyl or together with R 3 forms C 2 . 6 alkylene;
- R 5 is substituted or unsubstituted acyl (e.g., formyl, carboxy, amide or ester), oxymethyl, iminomethyl, or dioxymethylyne (e.g., -O-CH-O-); preferably (i) oxymethyl, for example, hydroxymethyl, e.g., generally R 6 O-CH , wherein R 6 is selected from H, alkyl, alkenyl, alkynyl, aryl, amino, acyl (e.g., alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, hydroxyalkylcarbonyl, aminoalkylcarbonyl, or formyl), thioalkyl, arylalkyl, hydroxyarylalkyl, hydroxyaryl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acy
- alk or “alkyl” refers to a Cj., 0 (preferably C U6 ) aliphatic substituent (branched, linear, or cyclic), optionally interrupted by an oxy (-O-) linkage; and "ar” or “aryl” refers to a monocyclic, optionally heterocyclic, optionally substituted, C 4 ., 4 aromatic substituent
- R 2 is of formula II, then R, is other than methyl and (i) R 3 is selected from hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, and aminoalkyl; and/or (ii) X is other than O; and/or (iii) R, is (optionally hydroxy- substituted) alkynyl , preferably (optionally hydroxy-substituted) alk-2-ynyl, e.g. prop-2- ynyl, but-2-ynyl, pent-2-ynyl, or 4-hydroxy-but-2-ynyl; and further provided that when R, is methyl, R 2 is of Formula III.
- Demethoxy rapamycins of Formula I also include
- R is selected from (i) benzyl, orr ⁇ o-alkoxybenzyl, and chlorobenzyl (especially benzyl or ⁇ rt/i ⁇ -methoxybenzyl), or (ii) (optionally hydroxy-substituted) alkynyl , preferably (optionally hydroxy-substituted) alk- 2-ynyl, especially (i) prop-2-ynyl, but-2-ynyl, pent-2-ynyl, and 4-hydroxy-but-2-ynyl; R 2 is of formula II; R 3 is selected from H, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, and aminoalkyl; R 4 is methyl; and X and Y are independently selected from O, (H,OH), and (H, C alkoxy); and most preferably, the 16-0 substituted rapamycins
- R is selected from alkyl, alkyenyl, alkynyl, aryl, thioalkyl, arylalkyl, hydroxyarylalkyl, hydroxyaryl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylamidoalkyl, acylamidoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxy alkyl, and alkylsilyl (especially alkynyl), wherein "alk” refers to C 0 aliphatic substituent (branched, linear, or cyclic), optionally interrupted by
- Y are as defined above; e.g., where R, is methyl, X and Y are O, and R 5 is substituted or unsubstituted acyl (e.g., formyl, carboxy, amide or ester), oxymethyl, iminomethyl, or dioxymethylyne (e.g., -O-CH-O-); e.g., (i) oxymethyl, e.g., R 6 O-CH 2 -, wherein R 6 is selected from H, alkyl, alkyenyl, alkynyl, aryl, thioalkyl, arylalkyl, hydroxyarylalkyl, hydroxyaryl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonyla
- Especially preferred compounds of Formula I include
- the compounds are produced from rapamycin or a rapamycin derivative generally as follows:
- the modification at the 16-0 can be produced either (i) by reaction of rapamycin or a rapamycin derivative with SeO 2 and a compound R r OH under suitable reaction conditions, e.g., at elevated temperatures, wherein R, is as defined above; or preferably (ii) by reaction of rapamycin or a rapamycin derivative with an acid, e.g., p- toluenesulphonic acid, and a nucleophile, e.g., R.-OH, at room temperature, in a suitable aprotic solvent, e.g., dichloromethane, acetonitrile, or THF.
- suitable aprotic solvent e.g., dichloromethane, acetonitrile, or THF.
- R 3 is an organic radical as defined above, e.g., an alkyl, allyl, or benzyl moiety, which is desired as the O-substituent, and Z is the leaving group, e.g., CCl 3 C(NH)O or CF 3 SO 3 ) under suitable reaction conditions, e.g., in the presence of an acid like trifluoromethanesulfonic acid, camphorsulfonic acid, p-toluenesulfonic acid or their respective pyridinium or substituted pyridinium salts when Z is CCl 3 C(NH)O or in the presence of a base like pyridine, a substituted pyridine, diisopropylethylamine or pent
- a leaving group e.g., R 3 -Z where R 3 is an organic radical as defined above, e.g., an alkyl, allyl, or benzyl moiety, which is desired as the O-substituent
- O- substitution or modification to make the other compounds of the invention is performed according to processes known to those skilled in the art, e.g., the following general processes: (i) for oxymethyl derivatives, the alcohol compound is reacted analogously as described above for 40-O-substitution; (ii) for acyl derivatives, the carboxylic acid compound is reacted with the desired amine or alcohol in the presence of an activating or coupling reagent, e.g., oxalylchloride or dicyclohexylcarbodiimide, to give the desired amide or ester compounds respectively; and (iii) for iminomethyl or dioxymethylyne compounds, the aldehyde compound is condensed with the desired amine or alkylenediol, respectively, under acidic conditions.
- an activating or coupling reagent e.g., oxalylchloride or dicyclohexylcarbodiimide
- the 32-O- dihydro compound (where X is (H,OH) is prepared by O-protecting the hydroxy groups, e.g., at positions 28 and 40 of rapamycin, e.g., using triethylsilyl ether protecting groups, reducing the protected compound, e.g., using L-selectride, and optionally deprotecting, e.g., under mildly acidic conditions, analogously to the method described in US 5 256 790 for preparation of 32-O-dihydro-rapamycin from rapamycin.
- the 28,40-O,O-protected compound is alkylated, e.g., as described for 40-O alkylation above, acylated, or otherwise O-substituted, e.g., analogously to the procedures described in US 5 256 790.
- the above processes may be carried out in any order, preferably using rapamycin as the ultimate starting material.
- the starting materials and intermediates may be protected (e.g., O-protected as described in process 4) before carrying out the above reaction(s) and then deprotected to obtain the desired final product.
- the Novel Compounds are particularly useful for the following conditions: a) Treatment and prevention of organ or tissue transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants; including treatment and prevention of acute rejection; treatment and prevention of hyperacute rejection, e.g., as associated with xenograft rejection; and treatment and prevention of chronic rejection, e.g., as associated with graft-vessel disease.
- the Novel Compounds are also indicated for the treatment and prevention of graft-versus-host disease, such as following bone marrow transplantation.
- autoimmune disease and of inflammatory conditions in particular inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
- an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
- Specific auto ⁇ immune diseases for which the compounds of the invention may be employed include, autoimmune hematological disorders (including e.g.
- hemolytic anaemia aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia
- systemic lupus erythematosus polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g.
- ulcerative colitis and Crohn's disease endocrine ophthalmopathy
- Graves disease sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.
- Treatment and prevention of asthma Treatment and prevention of asthma.
- MDR multi-drug resistance
- the Novel Compounds suppress P-glycoproteins (Pgp), which are the membrane transport molecules associated with MDR. MDR is particularly problematic in cancer patients and AIDS patients who will not respond to conventional chemotherapy because the medication is pumped out of the cells by Pgp.
- the Novel Compounds are therefore useful for enhancing the efficacy of other chemotherapeutic agents in the treatment and control of multidrug resistant conditions such as multidrug resistant cancer or multidrug resistant AIDS.
- e) Treatment of proliferative disorders, e.g. tumors, hyperproliferative skin disorder and the like.
- the invention thus provides the Novel Compounds described herein, for use as novel intermediates or as pharmaceuticals, methods of treating or preventing the above- described disorders by administering an effective amount of a Novel Compound to a patient in need thereof, use of a Novel Compound in the manufacture of a medicament for treatment or prevention of the above-described disorders, and pharmaceutical compositions comprising a Novel Compound in combination or association with a pharmaceutically acceptable diluent or carrier.
- the Novel Compounds are utilized by administration of a pharmaceutically effective dose in pharmaceutically acceptable form to a subject in need of treatment. Appropriate dosages of the Novel Compounds will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired and the mode of administration.
- Suitable daily dosages for patients are thus on the order of 500 mg p.o., e.g. on the order of from 5 to 100 mg p.o., or on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v..
- dosaging is arranged in patient specific manner to provide pre-determined trough blood levels, e.g. as determined by RIA technique.
- patient dosaging may be adjusted so as to achieve regular on-going trough blood levels as measured by RIA on the order of from 50 or 150 up to 500 or lOOOng/ml, i.e. analogously to methods of dosaging currently employed for Ciclosporin immunosuppressive therapy.
- the Novel Compounds may be administered as the sole active ingredient or together with other drugs.
- immunosuppressive applications such as prevention and treatment of graft vs. host disease, transplant rejection, or autoimmune disease
- the Novel Compounds may be used in combination with cyclosporins or ascomycins, or their immunosuppressive analogs, e.g., cyclosporin A, cyclosporin G, FK- 506, etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; brequinar; leflunomide; mizoribine; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, CTLA4, B7, CD45, or CD58 or their ligands; or other immunomodulatory compounds.
- the combination is most preferably with IL-2 transcription inhibitors such as the immunosuppressive cyclosprins (e.g., cyclosporin A) and ascomycins (e.g., FK-506).
- IL-2 transcription inhibitors such as the immunosuppressive cyclosprins (e.g., cyclosporin A) and ascomycins (e.g., FK-506).
- the Novel Compounds can also be used together with anti-inflammatory agents, e.g., corticosteroids.
- the Novel Compounds can be used in combination with other anti-infective agents, e.g., anti-viral drugs or antibiotics.
- the Novel Compounds are administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions.
- Suitable unit dosage forms for oral administration comprise, e.g. from 1 to 50 mg of a compound of the invention, usually 1 to 10 mg.
- Pharmaceutical compositions comprising the novel compounds may be prepared analogously to pharmaceutical compositions comprising rapamycin, e.g., as described in EPA 0 041 795, which would be evident to one skilled in the art.
- MLR Mixed lymphocyte reaction
- the Mixed Lymphocyte Reaction was originally developed in connection with allografts, to assess the tissue compatibility between potential organ donors and recipients, and is one of the best established models of immune reaction in vitro.
- a murine model MLR e.g., as described by T.Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227-239 (1979), is used to demonstrate the immunosuppressive effect of the Novel Compounds.
- Spleen cells 0.5 x 10 6
- Balb/c mice female.
- irradiated 2000 rads
- mitomycin C treated spleen cells from CBA mice (female, 8-10 weeks).
- the irradiated allogeneic cells induce a proliferative response in the Balb/c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity.
- the antiproliferative effect of the Novel Compounds on the Balb/c cells is measured at various dilutions and the concentration resulting in 50% inhibition of cell proliferation (IC 50 ) is calculated.
- the alkynyl derivatives of the examples are particularly potent immunosuppressants, with an IC 50 in this assay relative to rapamycin of 0.3 - 0.8, i.e., up to 3x more active than rapamycin.
- the capacity of the Novel Compounds to interfere with growth factor associated signalling pathways is assessed using an interleukin-6 (IL-6)-dependent mouse hybridoma cell line.
- the assay is performed in 96-well microtiter plates. 5000 cells/well are cultivated in serum-free medium (as described by M. H. Schreier and R. Tees in Immunological Methods, I. Lefkovits and B. Pernis, eds., Academic Press 1981 , Vol. II, pp. 263-275), supplemented with 1 ng recombinant IL-6/ml.
- Rapamycin and the structurally related immunosuppressant, FK-506, are both known to bind in vivo to macrophilin- 12 (also known as FK-506 binding protein or FKBP-12), and this binding is thought to be related to the immunosuppressive activity of these compounds.
- the Novel Compounds also bind strongly to macrophilin- 12, as is demonstrated in a competitive binding assay. In this assay, FK-506 coupled to BSA is used to coat microtiter wells. Biotinylated recombinant human macrophilin- 12 (biot-MAP) is allowed to bind in the presence or absence of a test sample to the immobilized FK-506.
- biot-MAP After washing (to remove non-specifically bound macrophilin), bound biot-MAP is assessed by incubation with a streptavidin-alkaline phosphatase conjugate, followed by washing and subsequent addition of p-nitrophenyl phosphate as a substrate. The read-out is the OD at 405nm. Binding of a test sample to biot-MAP results in a decrease in the amount of biot-MAP bound to the FK-506 and thus in a decrease in the OD405. A dilution series of the test sample allows determination of the concentration resulting in 50% inhibition of the biot-MAP binding to the immobilized FK-506 (IC 50 ). The exemplified Novel Compounds all exhibit good binding to FKBP in this assay.
- kidney from a female fisher 344 rat is transplanted onto the renal vessel of a unilaterally (left side) nephrectomized WF recipient rat using an end-to-end anastomosis. Ureteric anastomosis is also end-to-end. Treatment commences on the day of transplantation and is continued for 14 days. A contralateral nephrectomy is done seven days after transplantation, leaving the recipient relying on the performance of the donor kidney. Survival of the graft recipient is taken as the parameter for a functional graft.
- EAE Experimentally Induced Allergic Encephalomyelitis
- ED 50 is the oral dose in mg/kg which reduces the swelling (primary or secondary) to half of that of the controls.
- the antitumor activity of the Novel Compounds and their ability to enhance the performance of antitumor agents by alleviating multidrug resistance is demonstrated, e.g., by administration of an anticancer agent, e.g., colchicine or etoposide, to multidrug resistant cells and drug sensitive cells in vitro or to animals having multidrug resistant or drug sensitive tumors or infections, with and without co-administration of the Novel Compounds to be tested, and by administration of the Novel Compound alone.
- Such in vitro testing is performed employing any appropriate drug resistant cell line and control (parental) cell line, generated, e.g. as described by Ling et al., J. Cell. Physiol. 83 . .
- Ehrlich ascites carcinoma (EA) sub-lines resistant to drug substance DR, VC, AM, ET, TE or CC are developed by sequential transfer of EA cells to subsequent generations of BALB/c host mice in accordance with the methods described by Slater et al., J. Clin. Invest, 70, 1 131 (1982).
- Equivalent results may be obtained employing the Novel Compounds test models of comparable design, e.g. in vitro, or employing test animals infected with drug-resistant and drug sensitive viral strains, antibiotic (e.g. penicillin) resistant and sensitive bacterial strains, anti-mycotic resistant and sensitive fungal strains as well as drug resistant protozoal strains, e.g. Plasmodial strains, for example naturally occurring sub-strains of Plasmodium falciparum exhibiting acquired chemotherapeutic, anti-malarial drug resistance.
- antibiotic e.g. penicillin
- Plasmodial strains for example naturally occurring sub-strains of Plasmodium
- the macrophilin binding activity of the Novel Compounds also makes them useful in enhancing or potentiating the action of corticosteroids.
- This can be shown, e.g., in the murine mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter gene assay, e.g., as described in Ning, et al., J. Biol. Chem. (1993) 268: 6073.
- MMTV-CAT murine mammary tumor virus-chloramphenicol acetyltransferase
- Mip and Mip-like factors are virulence factors produced by a wide variety of pathogens, including those of the genera Chlamidia. e.g., Chlamidia trachomatis: Neisseria. e.g., Neisseria meningitidis: and Legionella. e.g., Legionella pneumophilia * . and also by the obligately parasitic members of the order Rickettsiales. These factors play a critical role in the establishment of intracellular infection.
- the efficacy of the Novel Compounds in reducing the infectivity of pathogens which produce Mip or Mip-like factors can be shown by comparing infectivity of the pathogens in cells culture in the presence and absence of the macrolides, e.g., using the methods described in Lundemose, et al., Mol. Microbiol. (1993) 7: 777.
- the Novel Compounds are also useful in assays to detect the presence or amount of macrophilin-binding compounds, e.g., in competitive assays for diagnostic or screening purposes.
- the invention provides for use of the Novel Compounds as a screening tool to determine the presence of macrophilin-binding compounds in a test solution, e.g., blood, blood serum, or test broth to be screened.
- a Novel Compound is immobilized in microtiter wells and then allowed to bind in the presence and absence of a test solution to labelled macrophilin- 12 (FKBP- 12).
- the FKBP-12 immobilized in microtiter wells and allowed to bind in the presence and absence of a test solution to a Novel Compound which has been labelled, e.g., fluoro-, enzymatically- or radio-labelled, e.g., a Novel Compound of Formula I wherein R j comprises a labelling group.
- a Novel Compound of Formula I wherein R j comprises a labelling group.
- the plates are washed and the amount of bound labelled compound is measured.
- the amount of macrophilin-binding substance in the test solution is roughly inversely proportional to the amount of bound labelled compound.
- a standard binding curve is made using known concentrations of macrophilin binding compound.
- rapamycin 1 mmol rapamycin is dissolved in 50 ml methylene chloride containing 3 ml of benzyl alcohol. 0.1 mmol of p-toluenesulphonic acid is added, and the reaction mixture is then stirred at room temperature for 2-10 hours. The reaction mixture is then poured in a saturated solution of sodium bicarbonate. The organic layer is separated, dried over sodium sulphate, and the solvent evaporated. The crude product is then purified by HPLC to give the pure title compound as a white powder.
- Example 8 16-demethoxy-40-O-(2-methoxyethyl)-16-(pent-2-ynyl)oxy -rapamycin
- To a solution of 0.7 ml 2-pentyn-l -ol in 5 ml CH 2 C1 2 are added 486 mg of 40-O-(2-methoxyethyl)-rapamycin followed by 5 mg p-toluenesulfonic acid.
- the mixture is stirred for 2 h at room temperature.
- the reaction is quenched with 7 ml of a saturated aqueous solution of NaHCO 3 .
- the aqueous phase is separated and extracted 2x with 10 ml ethyl acetate.
- Example 12 39-demethoxy-40-desoxy-39-(4-methyl-piperazin-l -vDcarbonyl-42-nor-rapamvcin
- Example 15 39-demethoxy-40-desoxy-39-(p-toluenesulfonylhvdrazonomethyl)-42-nor-rapamycin
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002174731A CA2174731C (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
US08/663,169 US5912253A (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives |
AT95903810T ATE191218T1 (en) | 1993-12-17 | 1994-12-16 | RAPAMYCIN DERIVATIVES AS IMMUNOSUPPRESSORS |
EP95903810A EP0734389B1 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
NZ277498A NZ277498A (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives |
DE69423781T DE69423781T2 (en) | 1993-12-17 | 1994-12-16 | RAPAMYCIN DERIVATIVES AS IMMUNO SUPPRESSORS |
AU12739/95A AU687491B2 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
JP51654495A JP3745772B2 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
BR9408323A BR9408323A (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives |
SI9430319T SI0734389T1 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
DK95903810T DK0734389T3 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
SK781-96A SK78196A3 (en) | 1993-12-17 | 1994-12-16 | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
NO962540A NO962540L (en) | 1993-12-17 | 1996-06-14 | Rapamycin derivatives for use as immunosuppressants |
FI962487A FI962487A0 (en) | 1993-12-17 | 1996-06-14 | rapamycin derivatives |
GR20000401237T GR3033545T3 (en) | 1993-12-17 | 2000-05-31 | Rapamycin derivatives useful as immunosuppressants |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939325802A GB9325802D0 (en) | 1993-12-17 | 1993-12-17 | Organic compounds |
GB9325802.8 | 1993-12-17 | ||
GB939325800A GB9325800D0 (en) | 1993-12-17 | 1993-12-17 | Organic compounds |
GB9325800.2 | 1993-12-17 | ||
GB9407138A GB9407138D0 (en) | 1994-04-11 | 1994-04-11 | Organic compounds |
GB9407138.8 | 1994-04-11 | ||
GB9421982A GB9421982D0 (en) | 1994-11-01 | 1994-11-01 | Organic compounds |
GB9421982.1 | 1994-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995016691A1 true WO1995016691A1 (en) | 1995-06-22 |
Family
ID=27451097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/004191 WO1995016691A1 (en) | 1993-12-17 | 1994-12-16 | Rapamycin derivatives useful as immunosuppressants |
Country Status (21)
Country | Link |
---|---|
US (1) | US5912253A (en) |
EP (1) | EP0734389B1 (en) |
JP (1) | JP3745772B2 (en) |
CN (1) | CN1046944C (en) |
AT (1) | ATE191218T1 (en) |
AU (1) | AU687491B2 (en) |
BR (1) | BR9408323A (en) |
CZ (1) | CZ284650B6 (en) |
DE (1) | DE69423781T2 (en) |
DK (1) | DK0734389T3 (en) |
ES (1) | ES2146741T3 (en) |
FI (1) | FI962487A0 (en) |
GR (1) | GR3033545T3 (en) |
HU (1) | HUT74686A (en) |
NO (1) | NO962540L (en) |
NZ (1) | NZ277498A (en) |
PL (1) | PL314238A1 (en) |
PT (1) | PT734389E (en) |
SG (1) | SG64372A1 (en) |
SK (1) | SK78196A3 (en) |
WO (1) | WO1995016691A1 (en) |
Cited By (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
WO2002066019A2 (en) * | 2001-02-19 | 2002-08-29 | Novartis Ag | Cancer treatment |
US6872383B2 (en) | 1999-04-30 | 2005-03-29 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
WO2005047295A1 (en) * | 2003-11-12 | 2005-05-26 | Sun Biomedical, Ltd. | 42-o-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7196192B2 (en) | 1999-08-24 | 2007-03-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7345053B2 (en) | 2002-12-16 | 2008-03-18 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
JP2009102349A (en) * | 1996-03-27 | 2009-05-14 | Novartis Ag | Use of rapamycin derivative in vasculopathy and xenotransplantation |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
EP2216019A2 (en) | 2005-03-04 | 2010-08-11 | Novartis AG | Ophthalmic uses of S1P receptor modulators |
EP2251007A2 (en) | 2002-09-24 | 2010-11-17 | Novartis AG | Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
EP2253320A1 (en) | 2005-07-20 | 2010-11-24 | Novartis AG | Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
US7931896B2 (en) | 2006-12-27 | 2011-04-26 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
EP2316377A1 (en) * | 2002-04-24 | 2011-05-04 | Biosensors International Group, Ltd. | Drug-Delivery Endovascular Stent And Method For Treating Restenosis |
AU2007201060B2 (en) * | 2001-02-19 | 2011-07-07 | Novartis Ag | Cancer treatment |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7993851B2 (en) | 2006-12-29 | 2011-08-09 | Abbott Laboratories | Lysis reagent for use with capture-in-solution immunoassay |
WO2011130232A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
WO2011128405A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Combination of organic compounds |
WO2011134899A1 (en) | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8129127B2 (en) | 2006-12-29 | 2012-03-06 | Abbott Laboratories | Assay for immunosuppressant drugs |
US8221986B2 (en) | 2006-12-29 | 2012-07-17 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
US8252046B2 (en) | 2002-04-24 | 2012-08-28 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2012148846A1 (en) | 2011-04-25 | 2012-11-01 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
WO2013155493A1 (en) | 2012-04-12 | 2013-10-17 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders |
WO2013192367A1 (en) | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
AU2011226833B2 (en) * | 2001-02-19 | 2014-05-22 | Novartis Ag | Cancer treatment |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
WO2015073644A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
WO2015121795A1 (en) | 2014-02-11 | 2015-08-20 | Novartis Ag | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2015149001A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
WO2015157252A1 (en) | 2014-04-07 | 2015-10-15 | BROGDON, Jennifer | Treatment of cancer using anti-cd19 chimeric antigen receptor |
WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
WO2016040806A1 (en) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | mTORC1 INHIBITORS |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
EP3011958A1 (en) | 2008-06-20 | 2016-04-27 | Novartis AG | Paediatric compositions for treating multiple sclerosis |
WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
US9359395B2 (en) | 2009-02-05 | 2016-06-07 | Tokai Pharmaceuticals, Inc. | Prodrugs of steroidal CYP17 inhibitors/antiandrogens |
US9387216B2 (en) | 2013-08-12 | 2016-07-12 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US9439912B2 (en) | 2013-03-14 | 2016-09-13 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2016142508A1 (en) | 2015-03-11 | 2016-09-15 | Centre Léon-Bérard | Composition for treating pancreatic neuroendocrine tumours |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
WO2017041053A1 (en) | 2015-09-04 | 2017-03-09 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
US9603925B2 (en) | 2013-01-09 | 2017-03-28 | University Of Miami | Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
WO2017173453A1 (en) | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
WO2017190145A1 (en) | 2016-04-29 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
WO2018057735A1 (en) | 2016-09-21 | 2018-03-29 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018096402A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US10098896B2 (en) | 2005-03-02 | 2018-10-16 | University Of Maryland Baltimore | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018217651A1 (en) | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
WO2019217552A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Particles for spatiotemporal release of agents |
WO2019217661A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020032252A1 (en) | 2018-08-10 | 2020-02-13 | 晃史 山口 | Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2020102730A1 (en) | 2018-11-16 | 2020-05-22 | Amgen Inc. | Improved synthesis of key intermediate of kras g12c inhibitor compound |
WO2020106647A2 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
WO2020129348A1 (en) | 2018-12-18 | 2020-06-25 | 晃史 山口 | Agent for improving infertility, recurrent miscarriage, and state of pregnancy |
WO2020132648A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2021001743A1 (en) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Translation inhibitors and uses thereof |
WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021026100A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
GB2586427A (en) * | 2019-01-22 | 2021-02-17 | Aeovian Pharmaceuticals Inc | MTORC modulators and uses thereof |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
WO2021086833A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021107160A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
WO2021258042A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
WO2022014640A1 (en) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Pyrimidine compound-containing combination to be used in tumor treatment |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
WO2022020522A3 (en) * | 2020-07-21 | 2022-03-03 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
EP3977995A1 (en) | 2014-10-28 | 2022-04-06 | Koushi Yamaguchi | Tacrolimus for ameliorating pregnancy conditions |
US11357851B2 (en) | 2015-11-11 | 2022-06-14 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
US11426404B2 (en) | 2019-05-14 | 2022-08-30 | Amgen Inc. | Dosing of KRAS inhibitor for treatment of cancers |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
US11603377B2 (en) | 2020-03-27 | 2023-03-14 | Aeovian Pharmaceuticals, Inc. | MTORC1 modulators and uses thereof |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
US11660329B2 (en) | 2012-11-14 | 2023-05-30 | University Of Cincinnati | Materials and methods useful for treating glioblastoma |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
US11859021B2 (en) | 2021-03-19 | 2024-01-02 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
DE69430060T2 (en) | 1993-04-23 | 2002-11-07 | Abbott Lab | RAPAMYCINE ANTIBODIES WITH OPEN RING |
US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
KR100400620B1 (en) | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | Rapamycin Derivatives |
WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20070032853A1 (en) * | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US7300662B2 (en) * | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
DE60124285T3 (en) | 2000-09-29 | 2011-03-17 | Cordis Corp., Miami Lakes | COATED MEDICAL EQUIPMENT |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
US20040241211A9 (en) * | 2000-11-06 | 2004-12-02 | Fischell Robert E. | Devices and methods for reducing scar tissue formation |
US6534693B2 (en) | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
CA2429722A1 (en) * | 2000-11-28 | 2002-06-06 | Wyeth | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP1458405A1 (en) * | 2001-11-21 | 2004-09-22 | Sucampo AG | Use of fk506 and analogues for treating allergic diseases |
US20040072796A1 (en) * | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
JP4265888B2 (en) * | 2002-06-12 | 2009-05-20 | 株式会社リコー | Image forming apparatus |
MXPA05000139A (en) | 2002-07-16 | 2005-04-11 | Biotica Tech Ltd | Production of polyketides and other natural products. |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US7585517B2 (en) * | 2003-09-18 | 2009-09-08 | Macusight, Inc. | Transscleral delivery |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20050142161A1 (en) * | 2003-12-30 | 2005-06-30 | Freeman Lynetta J. | Collagen matrix for soft tissue augmentation |
GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
US7901451B2 (en) * | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
SI1848431T1 (en) * | 2005-02-09 | 2016-05-31 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
KR20070116868A (en) | 2005-03-11 | 2007-12-11 | 바이오티카 테크놀로지 리미티드 | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
JP5528708B2 (en) | 2006-02-09 | 2014-06-25 | 参天製薬株式会社 | Stable formulations and methods for preparing and using them |
US8222271B2 (en) * | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
US20080097591A1 (en) | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
KR100930167B1 (en) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | Ultra wide angle optical system |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
CN101924315B (en) * | 2009-06-16 | 2014-09-03 | 德昌电机(深圳)有限公司 | Commutator and manufacturing method thereof |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
WO2015103447A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
CN103945850A (en) | 2011-11-15 | 2014-07-23 | 诺华股份有限公司 | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway |
GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
EP2869818A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
EP2906214A1 (en) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
DK2968281T3 (en) | 2013-03-13 | 2020-11-02 | Univ Texas | MTOR INHIBITORS FOR PREVENTING THE GROWTH OF THE INTESTINAL POLYPH |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA2968049A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
CN106188093B (en) * | 2015-05-08 | 2018-06-12 | 上海医药工业研究院 | A kind of rapamycin structure analog and preparation method thereof |
JP2020507632A (en) | 2017-02-10 | 2020-03-12 | マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. | Rapamycin analog |
WO2018213352A1 (en) | 2017-05-15 | 2018-11-22 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
EP3880266A1 (en) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
CN113939324A (en) | 2019-04-08 | 2022-01-14 | 巴德外周血管股份有限公司 | Medical devices having drug eluting coatings on modified device surfaces |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
WO1992005179A1 (en) * | 1990-09-19 | 1992-04-02 | American Home Products Corporation | Carboxylic acid esters of rapamycin |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2881886B2 (en) * | 1989-12-30 | 1999-04-12 | ソニー株式会社 | Video signal encoding method and apparatus therefor |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
JP4105761B2 (en) * | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | Semi-synthetic analog immunomodulator of rapamycin (macrolide) |
-
1994
- 1994-12-16 PT PT95903810T patent/PT734389E/en unknown
- 1994-12-16 ES ES95903810T patent/ES2146741T3/en not_active Expired - Lifetime
- 1994-12-16 AT AT95903810T patent/ATE191218T1/en not_active IP Right Cessation
- 1994-12-16 JP JP51654495A patent/JP3745772B2/en not_active Expired - Fee Related
- 1994-12-16 BR BR9408323A patent/BR9408323A/en not_active Application Discontinuation
- 1994-12-16 DE DE69423781T patent/DE69423781T2/en not_active Expired - Lifetime
- 1994-12-16 DK DK95903810T patent/DK0734389T3/en active
- 1994-12-16 CZ CZ961757A patent/CZ284650B6/en not_active IP Right Cessation
- 1994-12-16 US US08/663,169 patent/US5912253A/en not_active Expired - Fee Related
- 1994-12-16 SG SG1996009086A patent/SG64372A1/en unknown
- 1994-12-16 NZ NZ277498A patent/NZ277498A/en unknown
- 1994-12-16 WO PCT/EP1994/004191 patent/WO1995016691A1/en active IP Right Grant
- 1994-12-16 EP EP95903810A patent/EP0734389B1/en not_active Expired - Lifetime
- 1994-12-16 CN CN94194522A patent/CN1046944C/en not_active Expired - Fee Related
- 1994-12-16 SK SK781-96A patent/SK78196A3/en unknown
- 1994-12-16 HU HU9601643A patent/HUT74686A/en unknown
- 1994-12-16 PL PL94314238A patent/PL314238A1/en unknown
- 1994-12-16 AU AU12739/95A patent/AU687491B2/en not_active Ceased
-
1996
- 1996-06-14 NO NO962540A patent/NO962540L/en unknown
- 1996-06-14 FI FI962487A patent/FI962487A0/en unknown
-
2000
- 2000-05-31 GR GR20000401237T patent/GR3033545T3/en not_active IP Right Cessation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
WO1992005179A1 (en) * | 1990-09-19 | 1992-04-02 | American Home Products Corporation | Carboxylic acid esters of rapamycin |
US5120842B1 (en) * | 1991-04-01 | 1993-07-06 | A Failli Amedeo | |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
Cited By (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649595B2 (en) | 1995-06-07 | 2003-11-18 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using novel compounds |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
JP2009102349A (en) * | 1996-03-27 | 2009-05-14 | Novartis Ag | Use of rapamycin derivative in vasculopathy and xenotransplantation |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US6872383B2 (en) | 1999-04-30 | 2005-03-29 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7196192B2 (en) | 1999-08-24 | 2007-03-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US8853366B2 (en) | 2001-01-17 | 2014-10-07 | Emergent Product Development Seattle, Llc | Binding domain-immunoglobulin fusion proteins |
EP3345602A1 (en) | 2001-02-19 | 2018-07-11 | Novartis AG | Rapamycin derivative for treating advanced solid tumours |
AU2019222912B2 (en) * | 2001-02-19 | 2020-09-03 | Novartis Ag | Cancer treatment |
US8436010B2 (en) | 2001-02-19 | 2013-05-07 | Novartis Pharmaceuticals Corporation | Treatment of solid tumors with rapamycin derivatives |
AU2011226833B2 (en) * | 2001-02-19 | 2014-05-22 | Novartis Ag | Cancer treatment |
CZ303611B6 (en) * | 2001-02-19 | 2013-01-09 | Novartis Ag | Pharmaceutical compositions containing rapamycin derivative and intended for treating solid tumors |
EP2762140A1 (en) | 2001-02-19 | 2014-08-06 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
EP3342411A1 (en) | 2001-02-19 | 2018-07-04 | Novartis AG | Rapamycin derivative for treating pancreas cancer |
WO2002066019A2 (en) * | 2001-02-19 | 2002-08-29 | Novartis Ag | Cancer treatment |
EP2764865A2 (en) | 2001-02-19 | 2014-08-13 | Novartis AG | Cancer treatment |
AU2017276287B2 (en) * | 2001-02-19 | 2019-10-17 | Novartis Ag | Cancer treatment |
WO2002066019A3 (en) * | 2001-02-19 | 2002-10-24 | Novartis Ag | Cancer treatment |
EP2269603A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP2269604A1 (en) | 2001-02-19 | 2011-01-05 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
EP3351246A1 (en) | 2001-02-19 | 2018-07-25 | Novartis AG | Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis |
EP3406249A1 (en) | 2001-02-19 | 2018-11-28 | Novartis AG | Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor |
AU2007201060C1 (en) * | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
AU2016206379B2 (en) * | 2001-02-19 | 2017-09-14 | Novartis Ag | Cancer Treatment |
EP2783686A1 (en) | 2001-02-19 | 2014-10-01 | Novartis AG | Combination of a rapamycin derivative and letrozole for treating breast cancer |
EP2269604B1 (en) | 2001-02-19 | 2016-07-27 | Novartis AG | Treatment of solid kidney tumours with a rapamycin derivative |
CZ307637B6 (en) * | 2001-02-19 | 2019-01-23 | Novartis Ag | 40-O- (2-Hydroxyethyl) rapamycin as the only active ingredient in the treatment |
AU2007201060B2 (en) * | 2001-02-19 | 2011-07-07 | Novartis Ag | Cancer treatment |
US8877771B2 (en) | 2001-02-19 | 2014-11-04 | Novartis Pharmaceuticals Corporation | Treatment of solid tumors with rapamycin derivatives |
US8308795B2 (en) | 2001-11-05 | 2012-11-13 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of forming the same |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US8252046B2 (en) | 2002-04-24 | 2012-08-28 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US8715341B2 (en) | 2002-04-24 | 2014-05-06 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of forming the same |
EP2316377A1 (en) * | 2002-04-24 | 2011-05-04 | Biosensors International Group, Ltd. | Drug-Delivery Endovascular Stent And Method For Treating Restenosis |
US8545550B2 (en) | 2002-04-24 | 2013-10-01 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1955696A2 (en) | 2002-05-16 | 2008-08-13 | Novartis AG | Use of EDG receptor binding agents in cancer |
EP1944026A2 (en) | 2002-05-16 | 2008-07-16 | Novartis AG | Use of EDG receptor binding agents in cancer |
EP2251007A2 (en) | 2002-09-24 | 2010-11-17 | Novartis AG | Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases |
EP2255798A2 (en) | 2002-09-24 | 2010-12-01 | Novartis AG | Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis |
US7345053B2 (en) | 2002-12-16 | 2008-03-18 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
EP1852437A3 (en) * | 2003-11-12 | 2008-03-12 | Sun Biomedical, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
EP1852437A2 (en) | 2003-11-12 | 2007-11-07 | Sun Biomedical, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
WO2005047295A1 (en) * | 2003-11-12 | 2005-05-26 | Sun Biomedical, Ltd. | 42-o-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US10098896B2 (en) | 2005-03-02 | 2018-10-16 | University Of Maryland Baltimore | C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity |
EP2216019A2 (en) | 2005-03-04 | 2010-08-11 | Novartis AG | Ophthalmic uses of S1P receptor modulators |
EP2253320A1 (en) | 2005-07-20 | 2010-11-24 | Novartis AG | Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
US9839670B2 (en) | 2005-08-30 | 2017-12-12 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US11395846B2 (en) | 2005-08-30 | 2022-07-26 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US8541554B2 (en) | 2006-07-21 | 2013-09-24 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US9134321B2 (en) | 2006-12-27 | 2015-09-15 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7931896B2 (en) | 2006-12-27 | 2011-04-26 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
EP2586458A1 (en) | 2006-12-27 | 2013-05-01 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
US8697365B2 (en) | 2006-12-29 | 2014-04-15 | Abbott Laboratories | Non-denaturing lysis reagent |
US8329415B2 (en) | 2006-12-29 | 2012-12-11 | Abbott Laboratories | Lysis reagent for use with capture-in-solution immunoassay |
US8221986B2 (en) | 2006-12-29 | 2012-07-17 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
US8440416B2 (en) | 2006-12-29 | 2013-05-14 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
US8129127B2 (en) | 2006-12-29 | 2012-03-06 | Abbott Laboratories | Assay for immunosuppressant drugs |
US8404452B2 (en) | 2006-12-29 | 2013-03-26 | Abbott Laboratories | Assay for immunosuppressant drugs |
US7993851B2 (en) | 2006-12-29 | 2011-08-09 | Abbott Laboratories | Lysis reagent for use with capture-in-solution immunoassay |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
US9101609B2 (en) | 2008-04-11 | 2015-08-11 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
EP3545953A1 (en) | 2008-06-20 | 2019-10-02 | Novartis AG | Paediatric compositions for treating1 multiple sclerosis |
EP3011958A1 (en) | 2008-06-20 | 2016-04-27 | Novartis AG | Paediatric compositions for treating multiple sclerosis |
US9359395B2 (en) | 2009-02-05 | 2016-06-07 | Tokai Pharmaceuticals, Inc. | Prodrugs of steroidal CYP17 inhibitors/antiandrogens |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
US10934364B2 (en) | 2009-08-03 | 2021-03-02 | University Of Miami | Method for in vivo expansion of T regulatory cells |
WO2011026132A2 (en) | 2009-08-31 | 2011-03-03 | 1/3Acamplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US9011853B2 (en) | 2009-08-31 | 2015-04-21 | Amplimmune, Inc. | B7-H4 fusion proteins and methods of use thereof |
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
US9957312B2 (en) | 2009-08-31 | 2018-05-01 | Medimmune, Llc | B7-H4 fusion proteins and methods of use thereof |
WO2011130232A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
WO2011128405A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Combination of organic compounds |
WO2011134899A1 (en) | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
WO2012112847A1 (en) | 2011-02-18 | 2012-08-23 | Novartis Pharma Ag | mTOR/JAK INHIBITOR COMBINATION THERAPY |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2012148846A1 (en) | 2011-04-25 | 2012-11-01 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
US10500157B2 (en) | 2012-04-12 | 2019-12-10 | Yale University | Nanoparticle-mediated delivery of cytokines for maintenance of the regulatory T cell phenotype |
US11173119B2 (en) | 2012-04-12 | 2021-11-16 | Yale University | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents |
WO2013155493A1 (en) | 2012-04-12 | 2013-10-17 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders |
US10603276B2 (en) | 2012-04-12 | 2020-03-31 | Yale University | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents |
US10709664B2 (en) | 2012-04-12 | 2020-07-14 | Yale University | Nanolipogel comprising a polymeric matrix and a lipid shell |
WO2013192367A1 (en) | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
US11660329B2 (en) | 2012-11-14 | 2023-05-30 | University Of Cincinnati | Materials and methods useful for treating glioblastoma |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
USRE48599E1 (en) | 2013-01-09 | 2021-06-22 | University Of Miami | Compositions comprising TLIA-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
US9603925B2 (en) | 2013-01-09 | 2017-03-28 | University Of Miami | Compositions comprising TL1A-Ig fusion protein for the regulation of T regulatory cells, and methods for their use |
US9439912B2 (en) | 2013-03-14 | 2016-09-13 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
US9808472B2 (en) | 2013-08-12 | 2017-11-07 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US9387216B2 (en) | 2013-08-12 | 2016-07-12 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
WO2015073644A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
EP4026909A1 (en) | 2013-12-19 | 2022-07-13 | Novartis AG | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015121795A1 (en) | 2014-02-11 | 2015-08-20 | Novartis Ag | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
WO2015142661A1 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
WO2015149001A1 (en) | 2014-03-27 | 2015-10-01 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
WO2015157252A1 (en) | 2014-04-07 | 2015-10-15 | BROGDON, Jennifer | Treatment of cancer using anti-cd19 chimeric antigen receptor |
EP3888674A1 (en) | 2014-04-07 | 2021-10-06 | Novartis AG | Treatment of cancer using anti-cd19 chimeric antigen receptor |
WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016040806A1 (en) | 2014-09-11 | 2016-03-17 | The Regents Of The University Of California | mTORC1 INHIBITORS |
US10117945B2 (en) | 2014-09-11 | 2018-11-06 | The Regents Of The University Of California | mTORC1 inhibitors |
US11452780B2 (en) | 2014-09-11 | 2022-09-27 | The Regents Of The University Of California | Mtorc1 inhibitors |
US10646577B2 (en) | 2014-09-11 | 2020-05-12 | The Regents Of The University Of California | mTORC1 inhibitors |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016057705A1 (en) | 2014-10-08 | 2016-04-14 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
EP3977995A1 (en) | 2014-10-28 | 2022-04-06 | Koushi Yamaguchi | Tacrolimus for ameliorating pregnancy conditions |
WO2016142508A1 (en) | 2015-03-11 | 2016-09-15 | Centre Léon-Bérard | Composition for treating pancreatic neuroendocrine tumours |
WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
EP4234685A2 (en) | 2015-04-17 | 2023-08-30 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016185443A1 (en) | 2015-05-20 | 2016-11-24 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
US10864170B2 (en) | 2015-09-04 | 2020-12-15 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
EP4257126A2 (en) | 2015-09-04 | 2023-10-11 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
WO2017041053A1 (en) | 2015-09-04 | 2017-03-09 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
US11357851B2 (en) | 2015-11-11 | 2022-06-14 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
WO2017173453A1 (en) | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
WO2017190145A1 (en) | 2016-04-29 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
EP4014967A1 (en) | 2016-04-29 | 2022-06-22 | Icahn School of Medicine at Mount Sinai | Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis |
US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
WO2018057735A1 (en) | 2016-09-21 | 2018-03-29 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018096402A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
US10993940B2 (en) | 2016-11-23 | 2021-05-04 | Novartis Ag | Methods of enhancing immune response |
US11045463B2 (en) | 2016-11-23 | 2021-06-29 | Novartis Ag | Methods of enhancing immune response |
US10441584B2 (en) | 2016-11-23 | 2019-10-15 | Novartis Ag | Methods of enhancing immune response |
WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
US11285135B2 (en) | 2016-12-22 | 2022-03-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US10532042B2 (en) | 2016-12-22 | 2020-01-14 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP4001269A1 (en) | 2016-12-22 | 2022-05-25 | Amgen Inc. | Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018217651A1 (en) | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11905281B2 (en) | 2017-05-22 | 2024-02-20 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3974429A1 (en) | 2017-05-22 | 2022-03-30 | Amgen Inc. | Precursors of kras g12c inhibitors |
US10519146B2 (en) | 2017-05-22 | 2019-12-31 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11306087B2 (en) | 2017-09-08 | 2022-04-19 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
WO2019051291A1 (en) | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
EP4141005A1 (en) | 2017-09-08 | 2023-03-01 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
US11364300B2 (en) | 2018-05-01 | 2022-06-21 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
US11685749B2 (en) | 2018-05-01 | 2023-06-27 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US10980889B1 (en) | 2018-05-01 | 2021-04-20 | Revolution Medicines, Inc. | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11766436B2 (en) | 2018-05-04 | 2023-09-26 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11045484B2 (en) | 2018-05-04 | 2021-06-29 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019217661A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
WO2019217552A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Particles for spatiotemporal release of agents |
US11517628B2 (en) | 2018-05-09 | 2022-12-06 | Yale University | Particles for spatiotemporal release of agents |
WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
US10988485B2 (en) | 2018-05-10 | 2021-04-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
EP4268898A2 (en) | 2018-06-11 | 2023-11-01 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
WO2020050890A2 (en) | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP4302827A3 (en) * | 2018-06-15 | 2024-03-13 | JANSSEN Pharmaceutica NV | Rapamycin analogs and uses thereof |
US11944605B2 (en) | 2018-06-15 | 2024-04-02 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
US20190388401A1 (en) * | 2018-06-15 | 2019-12-26 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
EP3813946A4 (en) * | 2018-06-15 | 2022-06-01 | Anakuria Therapeutics, Inc. | Rapamycin analogs and uses thereof |
US10980784B2 (en) * | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020032252A1 (en) | 2018-08-10 | 2020-02-13 | 晃史 山口 | Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship |
WO2020102730A1 (en) | 2018-11-16 | 2020-05-22 | Amgen Inc. | Improved synthesis of key intermediate of kras g12c inhibitor compound |
US11299491B2 (en) | 2018-11-16 | 2022-04-12 | Amgen Inc. | Synthesis of key intermediate of KRAS G12C inhibitor compound |
EP4234546A2 (en) | 2018-11-16 | 2023-08-30 | Amgen Inc. | Improved synthesis of key intermediate of kras g12c inhibitor compound |
US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
WO2020106647A2 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
US11439645B2 (en) | 2018-11-19 | 2022-09-13 | Amgen Inc. | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
US11918584B2 (en) | 2018-11-19 | 2024-03-05 | Amgen Inc. | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
WO2020106640A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
WO2020129348A1 (en) | 2018-12-18 | 2020-06-25 | 晃史 山口 | Agent for improving infertility, recurrent miscarriage, and state of pregnancy |
WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
WO2020132648A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
KR20220034025A (en) * | 2019-01-22 | 2022-03-17 | 에오비안 파마슈티컬스, 인크. | MTORC modulators and uses thereof |
US11702429B2 (en) | 2019-01-22 | 2023-07-18 | Aeovian Pharmaceuticals, Inc. | mTORC modulators and uses thereof |
JP2022137237A (en) * | 2019-01-22 | 2022-09-21 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC modulators and uses thereof |
JP7288540B2 (en) | 2019-01-22 | 2023-06-07 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC modulators and uses thereof |
KR102643707B1 (en) | 2019-01-22 | 2024-03-04 | 에오비안 파마슈티컬스, 인크. | MTORC modulators and their uses |
GB2586427B (en) * | 2019-01-22 | 2022-02-09 | Aeovian Pharmaceuticals Inc | MTORC modulators and uses thereof |
EP3914245A4 (en) * | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
US11230557B2 (en) | 2019-01-22 | 2022-01-25 | Aeovian Pharmaceuticals, Inc. | mTORC modulators and uses thereof |
JP7108804B2 (en) | 2019-01-22 | 2022-07-28 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC modulators and uses thereof |
US11021492B2 (en) | 2019-01-22 | 2021-06-01 | Aeovian Pharmaceuticals, Inc. | mTORC modulators and uses thereof |
GB2586427A (en) * | 2019-01-22 | 2021-02-17 | Aeovian Pharmaceuticals Inc | MTORC modulators and uses thereof |
EP4272825A3 (en) * | 2019-01-22 | 2023-12-06 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
JP2022095907A (en) * | 2019-01-22 | 2022-06-28 | エオビアン ファーマシューティカルズ, インコーポレイテッド | Mtorc modulators and uses thereof |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
US11426404B2 (en) | 2019-05-14 | 2022-08-30 | Amgen Inc. | Dosing of KRAS inhibitor for treatment of cancers |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
US11827635B2 (en) | 2019-05-21 | 2023-11-28 | Amgen Inc. | Solid state forms |
WO2021001743A1 (en) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Translation inhibitors and uses thereof |
WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021026100A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
WO2021026098A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
WO2021086833A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
WO2021097212A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2021107160A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
EP4069223A4 (en) * | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | Rapamycin analogs and uses thereof |
US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
US11603377B2 (en) | 2020-03-27 | 2023-03-14 | Aeovian Pharmaceuticals, Inc. | MTORC1 modulators and uses thereof |
US11634432B2 (en) | 2020-03-27 | 2023-04-25 | Aeovian Pharmaceuticals, Inc. | mTORC1 modulators and uses thereof |
WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
WO2021258042A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
WO2022014640A1 (en) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Pyrimidine compound-containing combination to be used in tumor treatment |
CN116322677A (en) * | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | MTORC1 modulators and uses thereof |
WO2022020522A3 (en) * | 2020-07-21 | 2022-03-03 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2022060836A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
US11859021B2 (en) | 2021-03-19 | 2024-01-02 | Icahn School Of Medicine At Mount Sinai | Compounds for regulating trained immunity, and their methods of use |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022250170A1 (en) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Small molecule inhibitors of kras mutated proteins |
WO2023288046A1 (en) | 2021-07-15 | 2023-01-19 | President And Fellows Of Harvard College | Compositions and methods relating to cells with adhered particles |
WO2023060253A1 (en) | 2021-10-08 | 2023-04-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Also Published As
Publication number | Publication date |
---|---|
HUT74686A (en) | 1997-01-28 |
FI962487A (en) | 1996-06-14 |
SG64372A1 (en) | 1999-04-27 |
SK78196A3 (en) | 1997-02-05 |
HU9601643D0 (en) | 1996-08-28 |
PT734389E (en) | 2000-09-29 |
GR3033545T3 (en) | 2000-09-29 |
JPH09506604A (en) | 1997-06-30 |
ES2146741T3 (en) | 2000-08-16 |
AU687491B2 (en) | 1998-02-26 |
ATE191218T1 (en) | 2000-04-15 |
PL314238A1 (en) | 1996-09-02 |
NO962540D0 (en) | 1996-06-14 |
CN1046944C (en) | 1999-12-01 |
BR9408323A (en) | 1997-08-19 |
CZ175796A3 (en) | 1996-09-11 |
CN1137797A (en) | 1996-12-11 |
JP3745772B2 (en) | 2006-02-15 |
EP0734389B1 (en) | 2000-03-29 |
AU1273995A (en) | 1995-07-03 |
DK0734389T3 (en) | 2000-08-21 |
NZ277498A (en) | 1998-03-25 |
DE69423781T2 (en) | 2000-08-10 |
CZ284650B6 (en) | 1999-01-13 |
EP0734389A1 (en) | 1996-10-02 |
US5912253A (en) | 1999-06-15 |
DE69423781D1 (en) | 2000-05-04 |
NO962540L (en) | 1996-06-14 |
FI962487A0 (en) | 1996-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5912253A (en) | Rapamycin derivatives | |
US5985890A (en) | Rapamycin derivatives | |
EP0663916B1 (en) | O-alkylated rapamycin derivative and its use, particularly as immunosuppressant | |
CA2174731C (en) | Rapamycin derivatives useful as immunosuppressants | |
MXPA97009555A (en) | Derivatives of rapamic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94194522.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995903810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2174731 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 277498 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 78196 Country of ref document: SK Ref document number: PV1996-1757 Country of ref document: CZ Ref document number: 962487 Country of ref document: FI Ref document number: 08663169 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-1757 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995903810 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-1757 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995903810 Country of ref document: EP |